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Abstract
Oocyte in vitro maturation (IVM) is an assisted reproductive technology designed to obtain mature oocytes following culture of
immature cumulus–oocyte complexes collected from antral follicles. Although IVM has been practiced for decades and is no
longer considered experimental, the uptake of IVM in clinical practice is currently limited. The purpose of this review is to ensure
reproductivemedicine professionals understand the appropriate use of IVM drawn from the best available evidence supporting its
clinical potential and safety in selected patient groups. This group of scientists and fertility specialists, with expertise in IVM in
the ART laboratory and/or clinic, explore here the development of IVM towards acquisition of a non-experimental status and, in
addition, critically appraise the current and future role of IVM in human ART.
Keywords In vitro maturation (IVM) . Oocyte maturation . Onco-fertility . Fertility preservation . Polycystic ovary syndrome
(PCOS)
Introduction
Human ARTs (assisted reproductive technologies), while ini-
tiated to provide family building opportunities to subfertile or
infertile patients, have now expanded into an important branch
of contemporary medicine serving a far wider segment of the
global population than anticipated following the birth of
Louise Brown in 1978. From its humble beginnings, having
access to human gametes and embryos has expanded the
knowledge base upon which ARTs have flourished, providing
for the first time the opportunity to do original research in
human reproductive biology. Coming at a time of unprece-
dented technological breakthroughs, the ability to obtain and
analyze the molecular and physiological basis of gametogen-
esis and embryogenesis in humans has both enriched the prac-
tice of ARTs for the benefit of patients and opened new op-
portunities for clinical and basic scientists alike. After many
years of foundational study, in vitro maturation (IVM) has
now reached a point in the history of human ARTs where its
clinical utilization will both broaden and enrich the hopes of
practitioners and patients in the decades ahead. It is the singu-
lar purpose of this review to provide a platform for under-
standing how, why, and when IVM has entered the spectrum
of ARTs available to reproductive and regenerative medicine.
Historical landmarks in the development
of human IVM
In an ironic twist of fate, the first reports of IVF in the human
were the result of IVM using ovarian oocytes. Menkin and
Rock harnessed the potential of maturing oocytes in vitro
based on the long-standing collaboration between Rock and
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Pincus. The latter first reported IVM using rabbit ova [1] and
then subsequently using human oocytes [2]. Buoyed by their
collaboration, Menkin and Rock reported successful fertiliza-
tion of in vitro matured human ova [3, 4] (Fig. 1). In hindsight,
these first reports of human IVF using IVM oocytes were
notable for two reasons: they established the concept of spon-
taneous oocyte maturation in mammals when cumulus–
oocyte masses released from Graafian follicles displayed mei-
otic and developmental competence over a certain time inter-
val and, importantly, made the earliest stages of human devel-
opment experimentally tractable.
Fast forward to the 1960s, Edwards made significant in-
roads into IVM in the human (Fig. 1) (reviewed in [5]). The
kinetics and culture requirements for IVM were established
for several different mammalian species [6], including for hu-
man oocytes [7]. His landmark work on human oocyte IVM
established the kinetics of nuclear maturation showing meta-
phase 2 (MII) stage was reached at about 36 h [8]. And within
a few short years, his work with Bavister led to the successful
IVF of human IVM oocytes [9, 10]. The impetus to move in
the direction of clinical IVF, while not to draw upon IVM as a
step in the process, was realized from this pioneering work.
Moreover, that mammalian oocytes frommany species shared
the properties implicit to spontaneous maturation provided a
research platform for the next 40 years of progress in oocyte
biology, maturation being the final act.
While the next 20 years (1970–1990; Fig. 1) would bring
clinical IVM closer to translation, it was a pivotal period dur-
ing which fundamental insights into oocyte physiology were
made using animal models. The first IVM baby resulting from
immature oocytes derived from oocyte donors was reported in
1991 by Cha and colleagues [11]. Since that report, IVM
gained attention during the 1990s [12–14], primarily as a treat-
ment option to reduce the risk of ovarian hyperstimulation
syndrome (OHSS) associated with ovarian stimulation (OS),
especially for polycystic ovary syndrome (PCOS) patients
[15]. During this same time period, IVM became an experi-
mental platform for the discovery of how the dialogue be-
tween cumulus cells and the oocyte regulate both nuclear
and cytoplasmic maturation. At the heart of the debates bridg-
ing clinical and basic science for the next 20 years was the
need to understand the relationship between hormonal control
of oocyte maturation, its coupling to ovulation, and the mo-
lecular and cellular underpinnings of meiotic arrest and cell
cycle progression to MII.
From the initial efforts of Chian, Tan, and colleagues at
McGill University [16], various gonadotropin priming strate-
gies coupled with differences in IVM protocols between
clinics clouded the field [17], prompting calls for clarity re-
garding a simple and logical definition of oocyte IVM [18,
19]. Central to current and future efforts to bring IVM into the
realm of everyday human ARTs are major research advances
into the physiology of ovulation in mammals. From the earli-
est days implicating a single gonadotropin signal, capable of
blocking the delivery of meiotic arresting factors like cGMP
and cAMP, to the more recent elaboration of multiparametric
signaling cascades downstream of LH reception during ovu-
lation, the complexities and nuances emergent from 20 years
of research have led to the development of a laboratory plat-
form designed to mimic, to the best of our current capabilities,
what happens naturally in vivo (reviewed in [20, 21]).
Translation to the human has progressed [22, 23] due to three
central physiological parameters we now have a deeper un-
derstanding of:
A. Maintenance of the cumulus–oocyte dialogue is essential
to assure bioenergetic and metabolic support required to
achieve cytoplasmic maturation.
Fig. 1 Landmarks in the development of human IVM.Major stages in the
development of IVM beginning with studies using human oocytes and
initial attempts at IVF and during 1990–2000 decades, first uses in the
clinic, are shown. The last decade has witnessed modest expansion of
clinical usage, especially in areas of onco-fertility and fertility
preservation
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B. Signaling reciprocity between oocyte-secreted factors
and cumulus define temporal parameters for maturation
that establish developmental competence.
C. Coordination of ovulation with meiotic maturation in-
volves a series of metabolic and gene expression changes
in somatic granulosa cells and enclosed oocytes that can
now be reproducibly manipulated under in vitro
conditions.
Given these extraordinary advances in reproductive physi-
ology (as summarized below), it is imperative that IVM as-
sumes its role in human infertility treatment, prompting the
stated objective of this paper to raise the awareness from cli-
nicians, embryologists, and patients and recognize IVM as a
patient-friendly and efficient ART technique.
The challenge: to mimic in vivo oocyte
maturation in vitro
The central challenge facing the IVM field was the discovery
that IVM oocytes displayed reduced developmental compe-
tence compared to their in vivo matured counterparts. This
held true even for IVM in agricultural animals, where IVM
is used routinely for in vitro embryo production and has been
studied far more extensively than in humans [24]. In all mam-
mals, the follicular origin of the oocyte has a major impact on
its subsequent development potential [25, 26] (Fig. 2). It ap-
pears that once the oocyte is removed from its follicle, its
developmental potential is curtailed [26], which was recog-
nized early on as an obstacle that would have to be overcome
for IVM to succeed. During follicular development, few antral
follicles gain dominant follicle status, most being subordinate
and likely in varying states of atresia; heterogeneity of oocytes
retrieved for IVM is thus due to their derivation from follicles
at varying stages of development. Despite this, most oocytes
from most species resume meiosis spontaneously once freed
from follicles; human oocytes do this too although at a notably
lower frequency than most mammals [8]. Although IVM oo-
cytes are able to complete nuclear maturation, their ability to
be fertilized and support subsequent embryo development is
reliant on the inherent developmental competence of the oo-
cyte acquired in vivo (traditionally called cytoplasmic matu-
ration). Mammalian oocytes are largely transcriptionally qui-
escent during meiotic maturation, depending on processing of
stored transcripts for protein synthesis and post-translational
mechanisms to complete maturation, and acquire the compe-
tence to support early embryo development before embryo
zygote genome activation [27]. Other aspects of cytoplasmic
maturation including organelle redistribution, epigenetic and
membrane modifications [28], are essential for fertilization
and embryo development to proceed. Loss of synchrony be-
tween nuclear and cytoplasmic maturation, a common occur-
rence under in vitro conditions, is attributable to precocious
meiotic resumption in vitro of an oocyte which was still ac-
quiring developmental competence in vivo. This factor con-
stitutes a major obstacle to the goal of generating high quality
blastocysts from IVM oocytes.
Extraction from the follicular environment is inevitable for
oocyte IVM and with it, the loss of all somatic cell and follic-
ular fluid influences. However, several approaches can be
taken to mitigate the impact of in vitro culture on the oocyte.
The first is to try to mimic in vitro, as far as is possible, the
in vivo follicular environment for the oocyte including reten-
tion of the architectural integrity of the COC and maintenance
of meiotic arrest [29] (Fig. 3). Follicles prevent oocyte meiotic
Fig. 2 Differences between
conventional IVF and IVM. The
principal differences between
conventional IVF and IVM are
that in IVM cycles, patients
receive minimal or no ovarian
stimulation prior to OPU, oocytes
are collected from small-medium
sized antral follicles, and oocytes
are meiotically matured in vitro
from the germinal vesicle (GV) to
metaphase II (MII) stage.
Thereafter, mature IVM oocytes
are treated exactly as per mature
oocytes from conventional IVF.
Adapted from [25]
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resumption by maintaining high levels of intra-oocyte cAMP
through the infusion of natriuretic peptides and cGMP from
the follicular somatic cells to the oocyte, as demonstrated in
mouse and cow oocytes [30–33]. Hence, meiotic resumption
can be readily prevented, and the COC structure retained,
when oocytes from most mammalian species are cultured in
the presence of natriuretic peptides (NPPC) or cAMP hydro-
lysis inhibitors (e.g., IBMX) [34]. The second approach is to
include growth factors present in the follicular environment,
including those like the EGF-like peptides, that are physiolog-
ically upregulated during oocyte maturation in vivo [21].
Notably, IVM media formulations have not changed substan-
tially for decades. COCs, or naked oocytes, are cultured in
various media supplemented with protein sources (serum or
albumin) and gonadotropins. Most growth factors present in
the follicular environment are not utilized in current standard
IVM systems. As suggested by recent mouse and cow oocyte
studies [35, 36], addition of growth factors into the IVM me-
dium may yield oocytes with improved quality. These media
modifications will continue to follow the findings from future
research regarding the coordination of somatic cell–oocyte
interactions.
Laboratory and clinical approaches to IVM
The introduction of a variety of clinical and laboratory ap-
proaches to IVM has led to considerable confusion and debate
in the literature [18]. However, the traditional and broadly
accepted definition of IVM [37], as originally described by
Edwards [8], is the maturation of immature cumulus–oocyte
complexes (COCs) collected from antral follicles that progress
from the germinal vesicle (GV) stage through to MII in vitro
over a species-specific time period (Fig. 4A). Variations on
IVM theme are principally based on the administration of
gonadotropins to the patient with the aim of obtaining oocytes
with the highest developmental potential from larger antral
follicles (stimulation with FSH) and/or to enhance the propor-
tion of MII oocytes (through administration of a bolus of hCG
before oocyte retrieval).
In simple terms, the laboratory component of IVM in-
volves collection and culture of intact COCs over a time
course expected to yield MII oocytes. Thereafter, mature oo-
cytes and resultant embryos are treated exactly as they would
be in a conventional IVF cycle. COCs are typically cultured in
complex tissue culture-like mediumwith supplementation of a
protein source and hormones (e.g., FSH +/− hCG), for 30–48
h, usually under atmospheric oxygen. In this review, we will
not review the myriad of hormone, growth factor, and other
additives that have been tested in IVM media. However, it is
worth noting that there are three main recognized clinical IVM
laboratory protocols [37], the choice of which, to some extent,
is dictated by the clinical preparation of the patient prior to
oocyte collection (Fig. 4A–C). Rescue IVM of GV oocytes
from conventional IVF cycles is an additional consideration
[38] (Fig. 4D), although it is not considered a clinical IVM
procedure as it is a non-recommended and unconventional
clinical practice [39, 40]. Table 1 briefly outlines the pros
and cons of these different approaches to IVM.
The role of FSH priming
Ovarian stimulation (OS) before oocyte retrieval in IVM has
been applied with different protocols, including the use of
clomiphene citrate, letrozole, or recombinant or urinary
FSH. The most common OS protocol used and studied for
IVM is a short course of FSH administered to the patient
(FSH priming). FSH priming does not induce oocyte meiotic
resumption in vivo, so this protocol always yields immature
compact COCs after OPU (Fig. 4A, B). Based on extensive
animal studies, FSH priming enhances follicular development
and the meiotic and developmental competence of immature
Fig. 3 Oocyte–cumulus cell
communication is fundamental to
IVM success. Left, image of
human MII oocyte collected after
conventional ovarian stimulation
and prior to removal of cumulus
cells; note extensions from corona
cells towards the oocyte surface.
Confocal projection on the right is
of an immature germinal vesicle
(GV) stage bovine oocyte
illustrating compact corona cells
(top) sending numerous
transzonal projections (arrow)
that terminate on the oocyte cell
surface. Alexa 555-phalloidin
was used to label actin filaments
in confocal image
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oocytes in vivo [49, 50]. Nevertheless, when priming with
FSH results in follicle growth to a diameter of ~ 10 mm or
more, the recovery rate of COCs from these follicles using a
single lumen needle may be reduced [51]. Although the use of
FSH priming in IVM cycles is based on solid rationale from
animal studies and is quite common in clinical practice, there
is no strong evidence from clinical trials for its use in human
IVM [14, 41].
The first study suggesting that mild stimulation with FSH
may improve oocyte yield and maturation rates was reported
byWynn et al. [52]. In this study, a course of 600 IUwas used
for 5 days, starting from day 2 of the cycle. A small RCT in 28
women with PCOS showed that a course of recombinant FSH
for 3 days (150 IU daily from day 3 of the cycle), improved
oocyte MII competence and implantation rate of cleaved em-
bryos [42]. Nevertheless, FSH priming did not result in better
clinical outcomes in women who did not have PCOS [14, 41].
There has been no consensus on the dose and duration of FSH
priming for IVM, yet the common dosage is 150 IU of FSH
daily for 2 or 3 days, starting from day 2 or 3 of the cycle or
after a progestin withdrawal bleed [23, 53, 54]. Data from a
small RCT by Mikkelsen et al. [55] showed no difference in
apoptosis of granulosa cells and no difference in developmen-
tal competence of oocytes obtained, when oocyte retrieval was
done 3 days, compared with 2 days, after the last FSH
injection.
Recapitulating the follicle environment: the evolution
of biphasic IVM
Perhaps the most significant development in clinical IVM in
recent years (Fig. 1) is the introduction of biphasic IVM (also
called pre-IVM) into clinical practice (Fig. 4B). Although this
represents a significant new direction for human IVM, the
concept of pre-IVM has been in the animal literature for de-
cades [56–58]. The basic principles of biphasic IVM culture
systems are to (a) maintain the oocyte in vitro in a meiotically
arrested (GV) stage, (b) retain intact the physical contact and
paracrine signaling system of communication between oocyte
and cumulus cells (Fig. 3), (c) foster and maintain an
Fig. 4 Major IVM protocols. A The original IVM protocol [8], where
immature, GV-stage COCs are matured in vitro in one step to MII.
Patients may or may not receive prior FSH priming as in either case all
oocytes are at the GV stage at OPU.BA biphasic IVM protocol is a small
variation on standard IVM, the notable difference being the additional
pre-IVM culture step. Here, meiosis of immature cumulus-enclosed
oocytes is deliberately arrested for ~ 24 h, before moving COCs into a
meiosis promoting medium. Examples include the SPOM- and CAPA-
IVM protocols. Patients may receive prior FSH priming, but not hCG
priming, as the latter is incompatible with the need for intact compact
COCs in this platform. C Patients receive a bolus of hCG prior to OPU,
+/− prior FSH priming. A proportion (~ 10–20%) of oocytes are collected
at the MII stage, some resume meiosis in vivo but are not mature
(germinal vesicle breakdown (GVB) or MI), and the majority of
oocytes are at the GV stage. The different stages of meiosis at OPU
necessitate differing treatment in the laboratory: MII require fertilization
on the day of OPU, whereas the maturing and immature oocytes require
IVM culture. D This is the maturation in vitro of immature GV-stage
oocytes collected from conventional IVF cycles after OS and ovulation
triggering, mostly with hCG [38]. These are commonly regarded as
medically unusable oocytes and are usually discarded in most IVF
clinics [39]. These oocytes are usually naked, as oocytes are denuded of
cumulus cells after OPU prior to ICSI; hence, rescue IVM oocytes are
invariably cultured in a denuded state from the GV to MII stage in vitro
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environment that allows the acquisition of developmental
competence for the oocyte over ~ 24 h in the pre-IVM step,
and (d) elicit resumption of and progression of meiosis under
conditions mimicking the post-LH surge follicular environ-
ment (Fig. 4B) (reviewed in [34]). Refinement of these con-
cepts eventually led to the breakthrough application of biphas-
ic IVM to human oocytes in an IVM center in Belgium [22].
This proof-of-principle study in 30 oocyte donors represents a
seminal contribution to the clinical IVM field [22], as it dem-
onstrated the effectiveness of NPPC in human IVM, it dem-
onstrated that biphasic IVM is superior to standard IVM, and
it established the media formulation for “capacitation-IVM”
(CAPA-IVM) which has been used in subsequent clinical tri-
als. This study was followed by a safety study [59] and pilot
RCTs in an IVM center of expertise in Vietnam of standard
IVM versus biphasic IVM with favorable clinical outcomes
for the biphasic approach [43, 60]. This culminated in a large
RCT comparing the efficacy of biphasic IVM with conven-
tional IVF, in which patients in the IVM arm received 150 IU
of hMG daily for just 2 days, which was 5.5-fold less FSH
than patients received in the IVF arm of the trial [23].
Although the difference in live birth rate after the first embryo
transfer between biphasic IVM (35%) and conventional IVF
(43%) was only 8% [23], which illustrates the potential of
biphasic IVM to narrow the efficiency gap between IVM
and IVF, the higher number of usable embryos after conven-
tional IVF resulted in an almost 19% lower cumulative ongo-
ing pregnancy rate at 12 months after randomization per
started IVM cycle compared to conventional IVF.
Triggering before OPU (hCG priming)
hCG and GnRHa have been used for triggering before oocyte
retrieval in IVM, although most of the available data are with
hCG triggering. The first successful application of hCG
triggering before oocyte retrieval in IVM was reported in
1999 [61]. Since then, the use of hCG triggering in IVM has
been adopted by many centers. Often hCG triggering in IVM
is combined with a short course of FSH priming, except in the
context of urgent fertility preservation [62]. Nevertheless, OS
with FSH followed by a bolus of hCG may in many respects
be considered a “truncated IVF” cycle [18] (Fig. 4C).
The hypothesis is that hCG may promote the initiation of
oocyte maturation in vivo and the time course of oocyte mat-
uration in vitro is hastened, and hence, the mature oocyte rate
is increased. Therefore, it is possible that pregnancy rates may
be improved by priming with hCG prior to immature oocyte
retrieval [16]. The largest study of IVM using hCG triggering,
combined with FSH priming, included 921 PCOS women.
The oocyte maturation rate was 71% and the cumulative live
birth rate over 12 months after one IVM cycle was 33.4%
[46]. However, a Cochrane review recently found no conclu-
sive evidence that hCG triggering before oocyte retrieval and
IVM would have an effect on clinical pregnancy or live birth
rates [63]. The authors provided low quality evidence suggest-
ing that hCG priming may reduce clinical pregnancy rates,
although these findings were limited by the small size of the
data set. A recent RCT conducted on 172 cancer patients
having IVM for fertility preservation verified the dubious role
of ovulation triggering in IVM treatment. The authors found
no difference in number of retrieved oocytes or the number of
mature oocytes between the three interventions of no trigger-
ing, hCG triggering, or GnRH agonist triggering [64].
Fresh transfer or freeze-only for IVM?
In IVM cycles, the follicular phase and duration of endome-
trial exposure to adequate estradiol levels are much shorter
than in stimulated IVF/ICSI cycles. Yet, according to retro-
spective data, fresh embryo transfer (ET) was feasible for the




• Simple one-step culture system [8, 18]
•All oocytes at the same immature meiotic stage at
the start of culture [8, 41]
• Relatively low MII rates at ~ 50% [41–43]
• Modest embryo yield and live birth rates [41, 43, 44]
Biphasic
IVM
• Relatively high MII rates at ~ 70% [22]
• Good embryo yield and live birth rates [22, 23,
43]
• Additional laboratory burden due the extra day of culture [22]
• Has only recently been introduced in a limited number of IVM labs [23, 45]
hCG-primed
IVM
• Relatively high MII rates at ~ 70% [46] • Oocytes are collected at a mixture of meiotic stages [47]
• Additional laboratory burden due to at least two rounds of ICSI per OPU [18]
• IVM of GVB oocyte cohort is suboptimal as the exact extent of their meiotic
progression at start cannot be determined [47]
• Modest live birth rates [41, 47]
• Prohibitive to the use of any pre-IVM culture approach [34]
Rescue IVM • GV oocytes are common in conventional IVF
patients
•May generate additional embryos for transfer [38]
• Oocytes commonly have meiotic defects [48]
• IVM in the absence of cumulus cell support → poor oocyte quality [20, 27, 40]
• Questionable safety [39, 40]
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majority of IVM treatment cycles after a short FSH-priming
protocol for a least 3 days, with satisfactory pregnancy out-
comes, either using a non-triggered IVM protocol [65] or
hCG-triggered IVM protocol [66]. Nevertheless, based on
the observation, again with retrospective data, that live birth
rates after frozen ET (FET) were higher compared to fresh ET
[53, 54], it was suggested that endometrial quality in non-
hCG-triggered IVM cycles may be suboptimal for normal
embryo implantation. In a prospective cohort study of 68
women who underwent endometrial sampling, an aberrant
expression pattern of steroid receptors in endometrium in
non-hCG-triggered IVM cycles was observed as well as a
deficient mid-luteal histological signature of endometrial re-
ceptivity, possibly due to the combination of a short phase of
endometrial proliferation and exposure of the endometrium to
insufficient levels of progesterone [67]. Therefore, a freeze-
only strategy was proposed for non-hCG IVM cycles [44].
The only RCT comparing live birth rates between fresh trans-
fer or freeze-only strategies in non-hCG IVM cycles was pub-
lished recently, which showed that frozen transfer provided a
significantly higher live birth rate than fresh transfer [68]. In
parallel, there is also emerging evidence that success rates
after conventional OS and IVF in high responders [69] may
be improved when a freeze-all approach is adopted instead of
fresh embryo transfer. Although embryo cryopreservation has
gained widespread acceptance, a recent concern in the ap-
proach of women with PCOS who undergo FET is the obser-
vation that FET may be associated with an increased risk of
early pregnancy loss [70] and hypertensive disorders of preg-
nancy (HDP) [71], if FET is performed in hormonal replace-
ment therapy (HRT) cycles. This is possibly due to inadequate
progestin support [72]. In view of this, it seems mandatory to
develop efficient clinical protocols for FET that are associated
with a lower risk of adverse obstetric events in general and, in
particular, in women with PCOS who undergo IVM.
Selection of suitable patients for IVM
IVM of oocytes has been advocated as a safer alternative for
conventional OS because of the ability to avoid the side effects
and risks that are associated with OS in women with elevated
functional ovarian reserve [12], including OHSS and ovarian
torsion. In recent years, strategies have been developed to
reduce OHSS risk, and the adoption of GnRH agonist trigger-
ing in combination with a policy of freeze-all embryos can
eliminate the severe type of OHSS [73]. Therefore, clinicians
have become less concerned about hyperresponse after OS.
Furthermore, the observed relationship between high oocyte
yield and favorable cumulative live birth rates per IVF cycle
may be used as an argument by IVF practitioners to stimulate
the ovaries of predicted high responders with higher doses
than before the “freeze-all” era. Consequently, severe OHSS
has been diminished, but moderate OHSS persists in many
European countries [74] and in the USA [75]. Although the
majority of predicted high responders accept the inherent risk
of OS, a considerable proportion of women would embark on
a less efficient fertility treatment if the burden of the treatment
would be lower [76]. IVM could have an emerging role in this
specific group of patients, although it is currently unknown to
which extent women would accept a lower chance of preg-
nancy in return. Subfertile women with PCOS who are eligi-
ble for ART are probably the best candidates for IVM. PCOS
is the most common endocrine condition in women and has an
overall prevalence of approximately 10% according to the
diagnostic criteria. These women may expect to have suffi-
ciently high numbers of immature oocytes to make up for the
inherently lower efficiency of IVM compared to conventional
OS for IVF [77, 78]. Not only can women with PCOS exhibit
excessive response to OS, a subset of them, especially those
with hyperandrogenism and/or obesity, may have a narrow
window of optimal ovarian response: OS in these patients
requires frequent monitoring and may result in suboptimal
outcome if hypo-response is observed [79]. For these patients,
IVM may be an attractive option because monitoring of fol-
licular growth can be kept to a minimum and oocyte retrieval
for IVM can be scheduled at the patient’s convenience. In
view of this, after patient counseling and discussion of pros
and cons of conventional OS and IVM, a subset of patients
with PCOS may embrace IVM as an alternative, simplified,
and low-burden ART.
Anti-Müllerian hormone (AMH) correlates with the sever-
ity of the PCOS phenotype [80], with the highest AMH serum
levels found in women with the classical PCOS phenotype A,
characterized by PCO-like morphology of the ovaries, ovula-
tory dysfunction, and hyperandrogenism. Previous research
has shown that AMH as a proxy of oocyte yield is a strong
predictor of pregnancy after IVM [77]. In a retrospective co-
hort study encompassing 320 women with PCOS who
underwent IVM,Mackens et al. [81] illustrated the importance
of assigning a specific phenotype to women with PCOS,
based on a combination of Rotterdam criteria. Indeed, after
adjusting for potential confounders, the PCOS phenotype sig-
nificantly correlated with cumulative live birth rate (CLBR)
after IVM; patients with the classical PCOS phenotype A had
the highest CLBR (40% per started cycle) [81]. Although no
prospective studies have compared clinical outcome after
IVM and conventional OS in women with PCOS type A, such
a comparative study could be a valuable future endeavor.
IVM for fertility preservation
Cryopreservation of embryos or oocytes after conventional
OS is currently the most established technique for fertility
preservation (FP) in women who have not recently received
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gonadotoxic treatment [82]. However, OS is not possible in
prepubertal girls and may be contraindicated in women with
estrogen receptor positive breast cancer, although FSH-
induced hyperestradiolemia may be counteracted or avoided
with adjuvant therapies like selective estrogen receptor mod-
ulators or aromatase inhibitors [83]. In these cases, IVM of
oocytes harvested via transvaginal follicular aspiration or, al-
ternatively, derived from extracorporeal ovarian tissue may be
considered as suitable techniques for FP, although the inher-
ently lower meiotic and developmental potential of IVM oo-
cytes will inevitably mitigate the prospective chances of a live
birth in cancer survivors who return to use their vitrified IVM
oocytes, when compared to a similar number of oocytes that
are cryopreserved after conventional ovarian stimulation.
Data from a center of expertise in IVM for FP illustrate the
feasibility of transvaginal egg retrieval for IVM in the follic-
ular or luteal phase in 248 breast cancer patients included in a
FP program before neoadjuvant chemotherapy [62]. In this
largest series of cancer patients undergoing IVM for FP so
far, with a mean age of 31.5 ± 0.3 years, a mean number of
6.4 ± 0.3 mature oocytes were cryopreserved after IVM. The
feasibility and safety of performing IVM in emergency set-
tings has also been shown in women diagnosed with hemato-
logic diseases [84]. In cancer patients, the administration of a
bolus of hCG before oocyte retrieval has shown to not im-
prove the total number of mature oocytes for cryopreservation
[64]. The first livebirth following vitrification of in vitro ma-
tured oocytes harvested transvaginally demonstrates the utility
of IVM in the overall strategy of female FP [85] (Fig. 1).
Sonigo et al. [86] observed that antral follicle count and
AMH values above 28 follicles and 3.9 ng/mL, 20 follicles
and 3.7 ng/mL, and 19 follicles and 3.5 ng/mL were required
to obtain at least 15, 10, or 8 cryopreserved oocytes, respec-
tively, after transvaginal egg retrieval for standard IVM.
Based on these data, the concept of double IVM, implying
the repetition of IVM cycles even within a very short time
frame (< 10 days), may emerge as a viable and safe option
for increasing the number of mature eggs available for FP
[87].
In order to expand the sources of cryopreserved material in
cancer patients, IVM can be combined with oophorectomy or
ovarian biopsies from the contralateral ovary for cryopreser-
vation of ovarian cortex [88, 89]. Cumulus–oocytes com-
plexes recovered during processing of extracorporeal ovarian
tissue adds to the pool of available material [90–92]. Patients
with high risk of malignant invasion of the ovary, such as
borderline ovarian carcinoma [93], leukemia, neuroblastoma,
and Burkitt lymphoma, may be most suitable for IVM of
oocytes from excised ovarian tissue (OTO-IVM), given that
ovarian tissue transplantation poses inherent risks for tumor
reintroduction. However, OTO-IVM remains experimental
because the long-term safety studies have yet to be conducted.
Moreover, lower maturation rates were observed after OTO-
IVM [91], not unexpectedly, due to the fact that COCs derived
from non-selected antral follicles from patients of different
ages are unlikely to have completed key stages of
folliculogenesis and would not be well supported by standard
IVM protocols. The biphasic IVM platform described above
has already shown promising results for OTO-IVM [45].
IVM for resistant ovary syndrome
Resistant ovary syndrome (ROS) is a rare endocrine condition
characterized by hypergonadotropic anovulation (WHO
group 3) and infertility. Patients often suffer from primary or
secondary amenorrhea with timely and spontaneous onset of
secondary sexual characteristics [94, 95]. Serum levels of FSH
and LH are elevated, in spite of normal levels of AMH and
normal antral follicle counts [96]. The pathophysiology of this
syndrome relies on the inability of antral follicles to respond to
both endogenous and exogenous FSH. Genetic or immuno-
logic abnormalities may explain antral follicle unresponsive-
ness to FSH although the etiology remains often unexplained
[97, 98]. Mutations with loss of function [99, 100] and poly-
morphisms of the FSH receptor [101, 102] have been de-
scribed. For ROS patients, IVM is currently the only viable
alternative option to egg donation, with several live births
reported [103, 104].
IVM for poor responders
Women exhibiting a poor response to exogenous gonad-
otropins have a reduced chance of achieving pregnancy,
and the optimal management of these patients remains a
matter of debate. Among the approaches considered, the
practice of using high doses of gonadotropins in poor
responders has not been supported by evidence [105].
Despite reports of livebirths obtained after rescue IVM
[38, 106, 107] or unprimed immature oocyte retrieval
[108], IVM as practiced yielded limited success in poor
prognosis patients of either advanced reproductive age
and/or low ovarian reserve. Indeed, the success of IVM
relies heavily on the number of oocytes retrieved from a
patient, even more than in a conventional OS cycle for
IVF, due to the unpredictable recovery of COCs, subop-
timal meiotic maturation rates from IVM of ~ 50% [109],
and higher embryo attrition rate using IVM compared to
conventional OS [110]. In addition, the fact that AFC,
AMH, and total testosterone are the only independent
predictors of oocyte yield in PCOS patients undergoing
IVM [77] suggests that poor prognosis patients are not
well suited to IVM.
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IVM in women with oocyte maturation
defects
A small subset of infertile women exhibit oocyte meiotic mat-
uration defects, in which immature (GV, M1 stages) oocytes
are obtained after repeated conventional OS cycles [111].
These women have few alternatives available to them for in-
fertility treatment. Some patients have underlying genetic de-
fects in their oocytes [112] and IVM is unlikely to help their
infertility. In other patients the pathophysiological basis for
the disorder is unknown. The few case series deploying
IVM for these patients have yielded disappointing results
[103, 113]. Future developments with the IVM platform, in-
cluding the use of biphasic IVM systems where meiosis is
induced in vitro during the IVM phase (reviewed in [34]),
could offer new opportunities for patients affected by such
conditions.
Safety aspects of IVM
All information and data available to date suggest that IVM is
safe for both patients treated and children born from the tech-
nique [37, 114]. Indeed, for women with PCOS, IVM is less
hazardous than treatment with conventional OS and IVF as
the risk of OHSS is eliminated in IVM pregnancies [23, 54].
For some time, there were concerns about the higher rate of
miscarriage in IVM cycles relative to conventional IVF [115],
which is now know to be attributable to the use of fresh ET in
IVM cycles [54], and hence with the adoption of a freeze-all
strategy for IVM, miscarriage rates are the same as in conven-
tional IVF [23]. In terms of pregnancy and obstetric compli-
cations, outcomes are not different for IVM and conventional
IVF pregnancies in terms of rates of ectopic pregnancies, ges-
tational diabetes, and antepartum hemorrhage [23, 114]. One
study found a significant increase in hypertensive disorders of
pregnancy in IVM compared to IVF pregnancies [116], but
this was not found in the subsequent prospective RCT of
biphasic IVM versus conventional IVF [23].
In terms of fetal and neonatal development, some concerns
have been expressed about possible epigenetic risks for IVM
children as oocyte meiosis occurs in vitro. The two studies to
date that have examined the status of key imprinted genes in
human IVM oocytes [59, 117] suggest that IVM does not
interfere with genomic imprinting establishment. This is cor-
roborated by imprinting studies using chorionic villus and
cord blood samples from children born from IVM [118].
Consistent with findings from these epigenetic studies, recent
conclusions from a meta-analysis [114] and from a RCT [23]
found that the major measures of neonatal outcomes are not
different between IVM and IVF babies, including preterm
birth, spontaneous preterm birth, iatrogenic preterm birth,
low or high birth weight, large for gestational age birth,
congenital anomalies, and admission to the neonatal intensive
care unit.
Follow-up studies of 2-year-old IVM children show nor-
mal growth and body weight compared to OS-IVF children,
and there is no evidence of a delay in mental development in
IVM children [119–121]. A long-term follow-up study of
IVM children and adolescents up the age of 19 found no
increased risk associated with IVM compared to IVF [122].
Collectively, these studies provide a degree of reassurance that
outcomes for mothers and children born from IVM do not
differ from conventional OS-IVF [114]; however, to date,
IVM numbers remain low and ongoing follow-up studies of
IVM children are warranted.
Divergent regional perspectives on the role
of IVM
Access to reproductive health care is excellent in European
countries. Large numbers of reproductive medicine centers
continue to contribute high level of safety and efficiency mea-
sures in current ART treatment options. Despite the linear
relationship between cumulative birth rates and ovarian re-
sponse after conventional OS and IVF/ICSI, even while the
risk of iatrogenic complications and side effects has been re-
duced during the past decade, the perceived burden by patients
of conventional OS remains high, especially in predicted high
responders [76]. In women with excessive antral follicle
counts, IVM has a better safety profile and may be advocated
as a minimal-burden treatment option [123]. After balanced
counseling of pros and cons of IVM compared to convention-
al OS, the tendency towards mild stimulation treatment with
relatively lower success rates may appeal to a subset of high
responders in countries where the out-of-pocket cost for the
patient undergoing ART is relatively low (Table 2).
The potential adoption of IVM in the ART clinics in
Europe, and to a large extent in Australia and New Zealand,
is in sharp contrast with prospects in the USA and Canada
(Table 2). In North America, the projected uptake of IVM in
ART clinics will be lower unless the efficiency of IVM culture
systems can be markedly improved. ART practice patterns in
the USA continue to follow ASRM guidelines in most clinics
according to recent SART data. Historically, US clinics have
been quick to adopt variations in protocols that increase mar-
keting potential in a competitive atmosphere expected to be
driven by capitalism. Hence, the rapid evolution of conven-
tional OS strategies, freeze-all cycles, oocyte banking, and
genetic testing approaches, all of which move into daily prac-
tice at a rate far in excess of more discriminating countries
around the world. Given this backdrop, IVM has received
little attention in the USA, admittedly in part because the latest
advances in ovarian physiology that have formed the corner-
stone of, for example, biphasic IVM, have yet to be fully
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Incentive for IVM for infertility treatment Incentive for IVM for onco-
fertility preservation
Europe +++ + Low incentive:
- Reduced efficiency compared to OS
- Utilization of freeze-all strategies in
high responders
- Limited cost savings for the patient
High incentive:
- Utilization will grow as more
centers develop expertise in
IVM




+++ +++ Low incentive:
- High cost of ART for patients means
prioritizing treatments with maximal
efficiency
High incentive:
- Utilization will increase as more
centers develop expertise in
IVM
- Focus on OTO-IVM in spite of
experimental nature
Russia +++ ++ Low incentive:
- Relatively high cost of ART for patients
means prioritizing treatments with
maximal efficiency
High incentive:
- Utilization will grow as more
centers develop expertise in
IVM





++ ++ High incentive:
- High incidence of patients with severe
PCOS and underutilized safety measures
in high responders
- Limited uptake because of lack of experienced
centers in the region and perceived complexity
of clinical and laboratory IVM procedures
Low incentive:
- Limited availability of
onco-fertility programs in the
region
India +++ ++ High incentive:
- High incidence of patients with severe PCOS
and underutilized safety measures in high
responders
- Limited uptake because of lack of experienced
centers in the region and perceived complexity
of clinical and laboratory IVM procedures
High incentive:
- Utilization will grow as more




++ ++ High incentive:
- High relative cost of gonadotropins
- Increasing uptake in view of emerging number
of centers in the region developing a high level
of expertise in IVM
High incentive:
- Utilization will grow as more
centers develop expertise in
IVM
- Focus on OTO-IVM in spite of
experimental nature
China ++ ++ Low incentive:
- High cost of ART for patients means prioritizing
treatments with maximal efficiency
Low incentive:
- Limited availability of





+++ + Low incentive:
- Reduced efficiency compared to OS
- Utilization of freeze-all strategies in high responders
- Limited cost savings for the patient
High incentive:
- Utilization will grow as more
centers develop expertise in
IVM





+++ + Low incentive:
- Reduced efficiency compared to OS
- Utilization of freeze-all strategies in high responders
- Limited cost savings for the patient
High incentive:
- Utilization will grow as more
centers develop expertise in
IVM





++ ++ Low incentive:
- Lack of experienced centers in the region and perceived
complexity of clinical and laboratory IVM procedures
Low incentive:
- Limited availability of
onco-fertility programs in the
region
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appreciated. The much-needed change in attitude for the fu-
ture will hopefully be prompted by this contribution to this
special issue of JARG.
IVMwas developed decades ago in South Korea and Japan
[11], with many IVM programs continuing today. While the
actual costs associated with one IVM cycle may be less than
for one IVF cycle [124–126] in many Western countries, a
major portion of IVF treatment or medication costs are often
covered by public health and/or health insurance; therefore,
IVM is not necessarily less expensive for infertile couples.
Moreover, as long as IVM is less efficacious compared to
conventional IVF, the cost for a baby using IVM may not be
lower in many health care settings. In contrast, in countries
with emerging economies, there is often no reimbursement
system for infertility treatment. Therefore, IVM can be a more
affordable ART lowering the out-of-pocket expenses for pa-
tients. In this sense, IVM could be even more attractive to
infertile patients in lower income countries in SE Asia
(Table 2). In fact, this is likely one of the principal drivers of
the uptake of IVM in the many Asian ART centers with on-
going active IVM programs in China, Vietnam, India,
Indonesia, Malaysia, and Thailand. By contrast, patients in
South Korea and Japan are less likely to be motivated by the
lower costs of IVM, even though they partly pay out-of-
pocket for ART treatment, such that patients in these two
countries have similar motivators to do IVM as patients in
Europe and Australia.
The need to develop a consortium of centers
of expertise in IVM
As with any emerging ART, an anticipated barrier to clin-
ical uptake of IVM will be access to clinical and labora-
tory knowhow of how to perform IVM. As IVM has been
practiced for decades (but with low cycle numbers), there
is in fact considerable literature on IVM. However, more
recently, a major shortcoming of the human IVM litera-
ture is the enormous degree of confusion about what it is,
and what it is not, and what constitutes clinically accept-
able IVM practice [18], e.g., rescue IVM is very often
conflated with standard IVM, when in fact rescue IVM
has questionable safety and should probably not be prac-
ticed [37]. Consequently, many clinical practitioners are
unclear about the current clinical status of IVM. A major
gap for the field has been the need for a consensus state-
ment on the clinical practice of IVM, something that in
many respects has been addressed by the recent ASRM
Committee Opinion on IVM declaring IVM non-
experimental [37]. In addition, clinics are likely to be
unsure how to implement an IVM practice. Importantly,
IVM is substantially less technically demanding for em-
bryologists to learn, compared to learning ICSI or embryo
biopsy, and requires no additional laboratory equipment,
although it does represent an extra procedure in the labo-
ratory. Oocyte retrieval is more challenging in an IVM
cycle compared to an IVF cycle; however, adaptations to
standard retrieval technique enable any clinician to per-
form oocyte retrieval for IVM in most patients [127].
Moreover, clinical management and cycle monitoring of
patients is greatly simplified compared to conventional
OS or even ovulation induction cycles. Nonetheless, a
misguided and insufficient understanding across the
ART sector of what constitutes IVM, coupled with lack
of sufficient centers of expertise that offer training in
IVM, comprises current barriers to uptake and progress
in IVM. In the past, pioneering clinical IVM hubs, such
as those in Melbourne, Seoul, Osaka, Copenhagen,
Monza, and Montreal, were instrumental in driving devel-
opments in IVM and accepting visitors from other clinics
for training. These days the centers of expertise have
shifted, to some extent, to Brussels, Paris, Tel Aviv, Ho
Chi Minh City, and multiple locations in China including
Guangzhou, Beijing, and Nanjing. It is imperative that
these leading centers continue to pass on their expertise
by offering training, including in the form of workshops,
and that these are supported by industry and academic
societies, such as the large and highly successful 2018
ASPIRE Masterclass in IVM, hosted by My Duc
Hospital in Ho Chi Minh City, Vietnam. It is only through
such concerted and collaborative effort by leading clini-
cians, scientists, academia and industry that IVM will ob-
tain a foothold in routine ART practice, such that patients,













+ ++ Low incentive:
- Lack of experienced centers in the region and perceived
complexity of clinical and laboratory IVM procedures
Low incentive:
- Limited availability of
onco-fertility programs in the
region
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health and financial benefits that comes from infertility
treatment with IVM.
Gaps for future IVM research
1. Improving embryo yield from IVM: Despite recent im-
provements, a recognized need will be to improve blasto-
cyst rates from IVM oocytes. This requires innovative and
sophisticated new IVM culture systems, built on the latest
scientific advances guided by continued animal oocyte
biology research.
2. Improving the recovery rate of oocytes in an IVM OPU:
The efficiency of IVMwould be significantly enhanced if
a higher proportion of oocytes could be recovered per
follicle aspirated. This will require development of novel
and sophisticated needle technology.
3. New clinical approaches to patient management: Can we
further simplify patient management prior to IVM, such
that cycle monitoring/management may not be needed at
all? Further refinements on approaches such as random-
start and the use of hormonal pretreatment are warranted.
4. IVM as part of standard practice in fertility preservation:
IVM should be routinely integrated into the repertoire of
technologies needed to maximize fertility preservation
prospects for cancer patients. Research is needed on
how to integrate the technology options of conventional
OS with OPU-IVM, OTO-IVM, and ovarian tissue cryo-
preservation into clinical practice. In addition, studies in-
tegrating follicle in vitro growth technologies with pre-
IVM are needed [128].
5. IVM and planned oocyte cryopreservation: Due to the
convenient, lower cost, and mild stimulation nature of
IVM, it provides an alternative for women seeking
planned oocyte cryopreservation, especially younger
women with a high AFC and AMH. To date, this ap-
proach has been poorly exploited and further research is
needed.
6. Towards zero-stimulation ART: Furthering the develop-
ment of sophisticated culture systems capable of
supporting the growth and differentiation of oocytes prior
to meiotic maturation, followed by IVM, will position the
ART field to a point where minimal or zero stimulation is
used.
Summary points
& IVM of oocytes refers to the in vitro culture of cumulus-
enclosed oocytes retrieved at the GV stage in medium that
supports oocyte developmental potential.
& IVM is a non-experimental procedure as it has been prac-
ticed for several decades and the evidence to date suggests
it is safe for women and offspring.
& IVM is a low intervention, mild approach to ART, well
suited to patients with an excessive antral follicle count
and is not suitable for poor prognosis patients.
& Although the technology is not new, IVM is not widely
used, and incentives leading to enhanced uptake of its use
in the ART clinic vary widely across the globe.
& With currently available IVM systems, clinical outcomes
are lower than those after conventional ovarian stimula-
tion in most women, but for some infertile women and
after appropriate counseling, the improved safety and a
simplified clinical approach will outweigh lower efficacy.
& Fertility preservation (FP) has enlarged the spectrum of
fertility disrupting conditions, such as cancer, by offering
a range of treatments that have evolved over the past de-
cade. IVM has been and will continue to serve this popu-
lation of patients in need of strategies to become parents
precluded by conventional ARTs.
Acknowledgements The authors wish to acknowledge the organizational
support provided by CooperSurgical for the preparation of this paper.
Funding IVM Research at Vrije Universiteit Brussel is supported by a
grant from the Fonds National de la Recherche Scientifique de Belgique–
the Excellence of Science (FNRS–EOS), number 30443682, awarded to
M.D.V. T.M.H.’s IVM research program is funded by the Vietnam
National Foundation for Science and Technology Development
(NAFOSTED; grant number FWO.106-YS.2017.02). Y.Y.’s IVM re-
search is funded by internal research funds provided by the Colorado
Center for Reproductive Medicine. R.B.G.’s IVM research program in
Sydney is funded by a grant (APP1139763) and fellowship
(APP1117538) from the National Health and Medical Research Council
of Australia and by support from City Fertility Global and Open
Philanthropy. D.F.A.’ research has been supported by the ESHE Fund.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
1276 J Assist Reprod Genet (2021) 38:1265–1280
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated oth-
erwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not permitted
by statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of
this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Pincus G, Enzmann EV. The comparative behavior of mammalian
eggs in vivo and in vitro: I. the activation of ovarian eggs. J Exp
Med. 1935;62:665–75.
2. Pincus G, Saunders B. The comparative behavior of mammalian
eggs in vivo and in vitro. VI. The maturation of human ovarian
ova. Anat Rec. 1939;75:537–45.
3. Rock J, Menkin MF. In vitro fertilization and cleavage of human
ovarian eggs. Science. 1944;100:105–7.
4. Menkin MF, Rock J. In vitro fertilization and cleavage of human
ovarian eggs. Am J Obstet Gynecol. 1948;55:440–52.
5. Thompson JG, Gilchrist RB. Pioneering contributions by Robert
Edwards to oocyte in vitro maturation (IVM). Mol Hum Reprod.
2013;19:794–8.
6. Edwards RG. Meiosis in ovarian oocytes of adult mammals.
Nature. 1962;196:446–50.
7. Edwards RG. Maturation in vitro of human ovarian oocytes.
Lancet. 1965;2:926–9.
8. Edwards RG. Maturation in vitro of mouse, sheep, cow, pig,
rhesus monkey and human ovarian oocytes. Nature. 1965;208:
349–51.
9. Edwards RG, Bavister BD, Steptoe PC. Early stages of fertiliza-
tion in vitro of human oocytes matured in vitro. Nature. 1969;221:
632–5.
10. Bavister BD, Edwards RG, Steptoe PC. Identification of the
midpiece and tail of the spermatozoon during fertilization of hu-
man eggs in vitro. J Reprod Fertil. 1969;20:159–60.
11. Cha KY, Koo JJ, Ko JJ, Choi DH, Han SY, Yoon TK. Pregnancy
after in vitro fertilization of human follicular oocytes collected
from nonstimulated cycles, their culture in vitro and their transfer
in a donor oocyte program. Fertil Steril. 1991;55:109–13.
12. Trounson A, Wood C. A Kausche. In vitro maturation and the
fertilization and developmental competence of oocytes recovered
from untreated polycystic ovarian patients. Fertil Steril. 1994;62:
353–62.
13. Barnes FL, Crombie A, Gardner DK, Kausche A, Kaplan OL,
Suikkari AM, et al. Blastocyst development and birth after in-
vitro maturation of human primary oocytes, intracytoplasmic
sperm injection and assisted hatching. Hum Reprod. 1995, 10:
3243–7.
14. Mikkelsen AL, Smith SD, Lindenberg S. In-vitro maturation of
human oocytes from regularly menstruating women may be suc-
cessful without follicle stimulating hormone priming. Hum
Reprod. 1999;14:1847–51.
15. Delvigne A, Rozenberg S. Epidemiology and prevention of ovar-
ian hyperstimulation syndrome (OHSS): a review. Hum Reprod
Update. 2002;8:559–77.
16. Chian RC, Buckett WM, Tulandi T, Tan SL. Prospective random-
ized study of human chorionic gonadotrophin priming before im-
mature oocyte retrieval from unstimulated women with polycystic
ovarian syndrome. Hum Reprod. 2000;15:165–70.
17. Dahan MH, Tan SL, Chung J, Son WY. Clinical definition paper
on in vitro maturation of human oocytes. Hum Reprod. 2016;31:
1383–6.
18. De VosM, Smitz J, Thompson JG. RBGilchrist. The definition of
IVM is clear-variations need defining. Hum Reprod. 2016;31:
2411–5.
19. Coticchio G. IVM in need of clear definitions. Hum Reprod.
2016;31:1387–9.
20. Gilchrist RB. Recent insights into oocyte-follicle cell interactions
provide opportunities for the development of new approaches to
in vitro maturation. Reprod Fertil Dev. 2011;23:23–31.
21. Richani D, Gilchrist RB. The epidermal growth factor network:
role in oocyte growth, maturation and developmental competence.
Hum Reprod Update. 2018;24:1–14.
22. Sanchez F, Lolicato F, Romero S, De Vos M, Van Ranst H,
Verheyen G, et al. An improved IVM method for cumulus-
oocyte complexes from small follicles in polycystic ovary syn-
drome patients enhances oocyte competence and embryo yield.
Hum Reprod. 2017;32:2056–68.
23. Vuong LN, Ho VNA, Ho TM, Dang VQ, Phung TH, Giang NH,
et al. In-vitro maturation of oocytes versus conventional IVF in
women with infertility and a high antral follicle count: a random-
ized non-inferiority controlled trial. Hum Reprod. 2020;35:2537–
47.
24. Lonergan P, et al. Maturation of oocytes in vitro. Annu Rev Anim
Biosci. 2016;4:255–68.
25. Thompson JG, RB Gilchrist, Improving oocyte maturation
in vitro., in Biology and Pathology of the oocyte: role in fertility,
medicine, and nuclear reprogramming, Second edition, G.R.
Trounson AO, Eichenlaub-Ritter U., Editor. 2013, Cambridge
University Press: Cambridge, UK 212-223.
26. Luciano AM, Sirard MA. Successful in vitro maturation of oo-
cytes: a matter of follicular differentiation. Biol Reprod. 2018;98:
162–9.
27. Conti M, Franciosi F. Acquisition of oocyte competence to devel-
op as an embryo: integrated nuclear and cytoplasmic events. Hum
Reprod Update. 2018;24:245–66.
28. McGinnis LK, Albertini DF. Dynamics of protein phosphoryla-
tion during meiotic maturation. J Assist Reprod Genet. 2010;27:
169–82.
29. Coticchio G, Canto MD, Renzini MM, Guglielmo MC,
Brambillasca F, Turchi D, et al. Oocyte maturation: gamete-
somatic cells interactions, meiotic resumption, cytoskeletal dy-
namics and cytoplasmic reorganization. Hum Reprod Update.
2015;21:427–54.
30. Vaccari S, JLWeeks, 2nd, M Hsieh, FS Menniti, M Conti. Cyclic
GMP signaling is involved in the luteinizing hormone-dependent
meiotic maturation of mouse oocytes. Biol Reprod. 2009;81:595–
604.
31. Norris RP, Ratzan WJ, Freudzon M, Mehlmann LM, Krall J,
Movsesian MA, et al. Cyclic GMP from the surrounding somatic
cells regulates cyclic AMP and meiosis in the mouse oocyte.
Development. 2009;136:1869–78.
32. Zhang M, Su YQ, Sugiura K, Xia G, Eppig JJ. Granulosa cell
ligand NPPC and its receptor NPR2 maintain meiotic arrest in
mouse oocytes. Science. 2010;330:366–9.
33. Franciosi F, Coticchio G, Lodde V, Tessaro I, Modina SC, Fadini
R, et al. Natriuretic peptide precursor C delays meiotic resumption
and sustains gap junction-mediated communication in bovine
cumulus-enclosed oocytes. Biol Reprod. 2014;91:61.
34. Gilchrist RB, Luciano AM, Richani D, Zeng HT, Wang X, Vos
MD, et al. Oocyte maturation and quality: role of cyclic nucleo-
tides. Reproduction. 2016;152:R143–57.
35. Sugimura S, Ritter LJ, Sutton-McDowall ML, Mottershead DG,
Thompson JG, Gilchrist RB. Amphiregulin co-operates with bone
morphogenetic protein 15 to increase bovine oocyte developmen-
tal competence: effects on gap junction-mediated metabolite sup-
ply. Mol Hum Reprod. 2014;20:499–513.
1277J Assist Reprod Genet (2021) 38:1265–1280
36. Stocker WA, Walton KL, Richani D, Chan KL, Beilby KH,
Finger BJ, et al. A variant of human growth differentiation
factor-9 that improves oocyte developmental competence. J Biol
Chem. 2020;295:7981–91.
37. Practice Committees of the American Society for Reproductive
Medicine tSoRB, Technologists, jao the Society for Assisted
Reproductive Technology. Electronic address. In vitro maturation:
a committee opinion. Fertil Steril. 2021;115:298–304.
38. Veeck LL, Wortham JW Jr, Witmyer J, Sandow BA, Acosta AA,
Garcia JE, et al. Maturation and fertilization of morphologically
immature human oocytes in a program of in vitro fertilization.
Fertil Steril. 1983;39:594–602.
39. Jie H, Zhao M, Alqawasmeh OAM, Chan CPS, Lee TL, Li T,
et al. In vitro rescue immature oocytes - a literature review. Hum
Fertil (Camb). 2021:1–20.
40. Jones GM, Cram DS, Song B, Magli MC, Gianaroli L, Lacham-
Kaplan O, et al. Gene expression profiling of human oocytes fol-
lowing in vivo or in vitro maturation. Hum Reprod. 2008;23:
1138–44.
41. Fadini R, Canto MBD, Renzini MM, Brambillasca F, Comi R,
Fumagalli D, et al. Effect of different gonadotrophin priming on
IVM of oocytes from women with normal ovaries: a prospective
randomized study. Reprod BioMed Online. 2009;19:343–51.
42. Mikkelsen AL, Lindenberg S. Benefit of FSH priming of women
with PCOS to the in vitromaturation procedure and the outcome: a
randomized prospective study. Reproduction. 2001;122:587–92.
43. Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S,
et al. Live births after oocyte in vitro maturation with a
prematuration step in women with polycystic ovary syndrome. J
Assist Reprod Genet. 2020;37:347–57.
44. Ortega-Hrepich C, Stoop D, Guzman L, Van Landuyt L,
Tournaye H, Smitz J, et al. A “freeze-all” embryo strategy after
in vitro maturation: a novel approach in women with polycystic
ovary syndrome? Fertil Steril. 2013;100:1002–7.
45. Kirillova A, Bunyaeva E, Van Ranst H, Khabas G,
Farmakovskaya M, Kamaletdinov N, et al. Improved maturation
competence of ovarian tissue oocytes using a biphasic in vitro
maturation system for patients with gynecological malignancy:
a study on sibling oocytes. J Assist Reprod Genet. 2021.
46. Ho VNA, Pham TD, Le AH, Ho TM, Vuong LN. Live birth rate
after human chorionic gonadotropin priming in vitro maturation in
women with polycystic ovary syndrome. J Ovarian Res. 2018;11:
70.
47. Son WY, Chung JT, Chian RC, Herrero B, Demirtas E, Elizur S,
et al. A 38 h interval between hCG priming and oocyte retrieval
increases in vivo and in vitro oocyte maturation rate in pro-
grammed IVM cycles. Hum Reprod. 2008;23:2010–6.
48. Nogueira D, Staessen C, Van de Velde H, Van Steirteghem A.
Nuclear status and cytogenetics of embryos derived from in vitro-
matured oocytes. Fertil Steril. 2000;74:295–8.
49. Eppig JJ, Schroeder AC, O’Brien MJ. Developmental capacity of
mouse oocytes matured in vitro: effects of gonadotrophic stimu-
lation, follicular origin and oocyte size. J Reprod Fertil. 1992;95:
119–27.
50. Gilchrist RB, Nayudu PL, Hodges JK. Maturation, fertilization,
and development of marmoset monkey oocytes in vitro. Biol
Reprod. 1997;56:238–46.
51. Rose BI, Laky D. A comparison of the Cook single lumen imma-
ture ovum IVM needle to the Steiner-Tan pseudo double lumen
flushing needle for oocyte retrieval for IVM. J Assist Reprod
Genet. 2013;30:855–60.
52. Wynn P, Picton HM, Krapez JA, Rutherford AJ, Balen AH,
Gosden RG. Pretreatment with follicle stimulating hormone pro-
motes the numbers of human oocytes reachingmetaphase II by in-
vitro maturation. Hum Reprod. 1998;13:3132–8.
53. De VosM, Ortega-Hrepich C, Albuz FK, Guzman L, Polyzos NP,
Smitz J, et al. Clinical outcome of non-hCG-primed oocyte in vitro
maturation treatment in patients with polycystic ovaries and poly-
cystic ovary syndrome. Fertil Steril. 2011;96:860–4.
54. Walls ML, Hunter T, Ryan JP, Keelan JA, Nathan E, Hart RJ.
In vitro maturation as an alternative to standard in vitro fertiliza-
tion for patients diagnosed with polycystic ovaries: a comparative
analysis of fresh, frozen and cumulative cycle outcomes. Hum
Reprod. 2015;30:88–96.
55. Mikkelsen AL, Host E, Blaabjerg J, Lindenberg S. Time interval
between FSH priming and aspiration of immature human oocytes
for in-vitro maturation: a prospective randomized study. Reprod
BioMed Online. 2003;6:416–20.
56. Funahashi H, Cantley TC, Day BN. Synchronization of meiosis in
porcine oocytes by exposure to dibutyryl cyclic adenosine
monophosphate improves developmental competence following
in vitro fertilization. Biol Reprod. 1997;57:49–53.
57. Nogueira D, Cortvrindt R, De Matos DG, Vanhoutte L, Smitz J.
Effect of phosphodiesterase type 3 inhibitor on developmental
competence of immature mouse oocytes in vitro. Biol Reprod.
2003;69:2045–52.
58. Thomas RE, Thompson JG, Armstrong DT, Gilchrist RB. Effect
of specific phosphodiesterase isoenzyme inhibitors during in vitro
maturation of bovine oocytes on meiotic and developmental ca-
pacity. Biol Reprod. 2004;71:1142–9.
59. Saenz-de-Juano MD, Ivanova E, Romero S, Lolicato F, Sanchez
F, Van Ranst H, et al. DNAmethylation and mRNA expression of
imprinted genes in blastocysts derived from an improved in vitro
maturation method for oocytes from small antral follicles in poly-
cystic ovary syndrome patients. Hum Reprod. 2019;34:1640–9.
60. Sanchez F, Le AH, HoVNA, Romero S, Van Ranst H, DeVosM,
et al. Biphasic in vitro maturation (CAPA-IVM) specifically im-
proves the developmental capacity of oocytes from small antral
follicles. J Assist Reprod Genet. 2019;36:2135–44.
61. Chian RC, Gulekli B, Buckett WM, Tan SL. Priming with human
chorionic gonadotropin before retrieval of immature oocytes in
women with infertility due to the polycystic ovary syndrome. N
Engl J Med. 1999;341:1624–6.
62. Grynberg M, Poulain M, le Parco S, Sifer C, Fanchin R, Frydman
N. Similar in vitro maturation rates of oocytes retrieved during the
follicular or luteal phase offer flexible options for urgent fertility
preservation in breast cancer patients. HumReprod. 2016;31:623–
9.
63. Reavey J, Vincent K, Child T, Granne IE. Human chorionic go-
nadotrophin priming for fertility treatment with in vitro matura-
tion. Cochrane Database Syst Rev. 2016;11:CD008720.
64. Sonigo C, Le Conte G, Boubaya M, Ohanyan H, Presse M, El
Hachem H, et al. Priming before in vitro maturation cycles in
cancer patients undergoing urgent fertility preservation: a random-
ized controlled study. Reprod Sci. 2020;27:2247–56.
65. Junk SM, Yeap D. Improved implantation and ongoing pregnancy
rates after single-embryo transfer with an optimized protocol for
in vitro oocyte maturation in women with polycystic ovaries and
polycystic ovary syndrome. Fertil Steril. 2012;98:888–92.
66. Ho VNA, Braam SC, Pham TD, Mol BW, Vuong LN. The effec-
tiveness and safety of in vitro maturation of oocytes versus in vitro
fertilization in women with a high antral follicle count. Hum
Reprod. 2019;34:1055–64.
67. Ortega-Hrepich C, Drakopoulos P, Bourgain C, Van Vaerenbergh
I, Guzman L, Tournaye H, et al. Aberrant endometrial steroid
receptor expression in in-vitro maturation cycles despite hormonal
luteal support: a pilot study. Reprod Biol. 2019;19:210–7.
68. Vuong LN, Nguyen LK, Le AH, Pham HH, Ho VN, Le HL, et al.
Fresh embryo transfer versus freeze-only after in vitro maturation
with a pre-maturation step in women with high antral follicle
1278 J Assist Reprod Genet (2021) 38:1265–1280
count: a randomized controlled pilot study. J Assist ReprodGenet.
2021.
69. Roque M, Haahr T, Geber S, Esteves SC, Humaidan P. Fresh
versus elective frozen embryo transfer in IVF/ICSI cycles: a sys-
tematic review and meta-analysis of reproductive outcomes. Hum
Reprod Update. 2019;25:2–14.
70. Tomas C, Alsbjerg B, Martikainen H, Humaidan P. Pregnancy
loss after frozen-embryo transfer–a comparison of three protocols.
Fertil Steril. 2012;98:1165–9.
71. von Versen-Hoynck F, Schaub AM, Chi YY, Chiu KH, Liu J,
Lingis M, et al. Increased preeclampsia risk and reduced aortic
compliance with in vitro fertilization cycles in the absence of a
corpus luteum. Hypertension. 2019;73:640–9.
72. Labarta E, Mariani G, Paolelli S, Rodriguez-Varela C, Vidal C,
Giles J, et al. Impact of low serum progesterone levels on the day
of embryo transfer on pregnancy outcome: a prospective cohort
study in artificial cycles with vaginal progesterone. Hum Reprod.
2021;36:683–92.
73. Ioannidou PG, Bosdou JK, Lainas GT, Lainas TG, Grimbizis GF,
Kolibianakis EM. How frequent is severe ovarian hyperstimula-
tion syndrome after GnRH agonist triggering in high-risk women?
A systematic review and meta-analysis. Reprod BioMed Online.
2021;42:635–50.
74. Calhaz-Jorge C, De Geyter C, Kupka MS, de Mouzon J, Erb K,
Mocanu E, et al. Assisted reproductive technology in Europe,
2013: results generated from European registers by ESHRE.
Hum Reprod. 2017;32:1957–73.
75. Rotshenker-Olshinka K, Badeghiesh A, Volodarsky-Perel A,
Steiner N, Suarthana E. MH Dahan. Trends in ovarian hyperstim-
ulation syndrome hospitalization rates in the USA: an ongoing
concern. Reprod BioMed Online. 2020;41:357–60.
76. Braam SC, de Bruin JP, Mol BWJ, van Wely M. The perspective
of womenwith an increased risk of OHSS regarding the safety and
burden of IVF: a discrete choice experiment. Hum Reprod Open.
2020;2020:hoz034.
77. Guzman L, Ortega-Hrepich C, Polyzos NP, Anckaert E, Verheyen
G, Coucke W, et al. A prediction model to select PCOS patients
suitable for IVM treatment based on anti-Mullerian hormone and
antral follicle count. Hum Reprod. 2013;28:1261–6.
78. Siristatidis C, Sergentanis TN, Vogiatzi P, Kanavidis P, Chrelias
C, Papantoniou N, et al. In Vitro maturation in women with vs.
without polycystic ovarian syndrome: a systematic review and
meta-analysis. PLoS One. 2015;10:e0134696.
79. De Vos M, Pareyn S, Drakopoulos P, Raimundo JM, Anckaert E,
Santos-Ribeiro S, et al. Cumulative live birth rates after IVF in
patients with polycystic ovaries: phenotype matters. Reprod
BioMed Online. 2018;37:163–71.
80. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P,
et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting
the threshold values of follicle count on ultrasound and of the
serum AMH level for the definition of polycystic ovaries. Hum
Reprod. 2011;26:3123–9.
81. Mackens S, Pareyn S, Drakopoulos P, Deckers T, Mostinckx L,
Blockeel C, et al. Outcome of in-vitro oocyte maturation in pa-
tients with PCOS: does phenotype have an impact? Hum Reprod.
2020;35:2272–9.
82. Donnez J, Dolmans MM. Fertility preservation in women. N Engl
J Med. 2017;377:1657–65.
83. Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander
M, et al. The safety and efficacy of controlled ovarian hyperstim-
ulation for fertility preservation inwomenwith early breast cancer:
a systematic review. Hum Reprod. 2017;32:1033–45.
84. Sonigo C, Bajeux J, Boubaya M, Eustache F, Sifer C, Levy V,
et al. In vitro maturation is a viable option for urgent fertility
preservation in young women with hematological conditions.
Hematol Oncol. 2020;38:560–4.
85. GrynbergM, AMayeur Le Bras, L Hesters, V Gallot, N Frydman.
First birth achieved after fertility preservation using vitrification of
in vitro matured oocytes in a woman with breast cancer. Ann
Oncol. 2020.
86. Sonigo C, Simon C, Boubaya M, Benoit A, Sifer C, Sermondade
N, et al. What threshold values of antral follicle count and serum
AMH levels should be considered for oocyte cryopreservation
after in vitro maturation? Hum Reprod. 2016;31:1493–500.
87. Sermondade N, Grynberg M, Comtet M, Valdelievre C, Sifer C,
Sonigo C. Double-in vitro maturation increases the number of
vitrified oocytes available for fertility preservation when ovarian
stimulation is unfeasible. Sci Rep. 2020;10:18555.
88. Wang X, Gook DA, Walters KA, Anazodo A, Ledger WL,
Gilchrist RB. Improving fertility preservation for girls and women
by coupling oocyte in vitro maturation with existing strategies.
Women Health. 2016;12(3):275–8.
89. Delattre S, Segers I, Van Moer E, Drakopoulos P, Mateizel I,
Enghels L, et al. Combining fertility preservation procedures to
spread the eggs across different baskets: a feasibility study. Hum
Reprod. 2020;35:2524–36.
90. Revel A, Koler M, Simon A, Lewin A, Laufer N, Safran A.
Oocyte collection during cryopreservation of the ovarian cortex.
Fertil Steril. 2003;79:1237–9.
91. Segers I, Bardhi E, Mateizel I, Van Moer E, Schots R, Verheyen
G, et al. Live births following fertility preservation using in-vitro
maturation of ovarian tissue oocytes. Hum Reprod. 2020;35:
2026–36.
92. Segers I, Mateizel I, Van Moer E, Smitz J, Tournaye H, Verheyen
G, et al. In vitro maturation (IVM) of oocytes recovered from
ovariectomy specimens in the laboratory: a promising “ex vivo”
method of oocyte cryopreservation resulting in the first report of
an ongoing pregnancy in Europe. J Assist Reprod Genet. 2015;32:
1221–31.
93. Huang JY, Buckett WM, Gilbert L, Tan SL, Chian RC. Retrieval
of immature oocytes followed by in vitro maturation and vitrifica-
tion: a case report on a new strategy of fertility preservation in
women with borderline ovarian malignancy. Gynecol Oncol.
2007;105:542–4.
94. Talbert LM, Raj MH, Hammond MG, Greer T. Endocrine and
immunologic studies in a patient with resistant ovary syndrome.
Fertil Steril. 1984;42:741–4.
95. Huhtaniemi I, Alevizaki M. Gonadotrophin resistance. Best Pract
Res Clin Endocrinol Metab. 2006;20:561–76.
96. Jones GS, De Moraes-Ruehsen M. A new syndrome of
amenorrhae in association with hypergonadotropism and appar-
ently normal ovarian follicular apparatus. Am J Obstet Gynecol.
1969;104:597–600.
97. Conway GS, Conway E, Walker C, Hoppner W, Gromoll J,
Simoni M. Mutation screening and isoform prevalence of the fol-
licle stimulating hormone receptor gene in women with premature
ovarian failure, resistant ovary syndrome and polycystic ovary
syndrome. Clin Endocrinol. 1999;51:97–9.
98. Haller-Kikkatalo K, Salumets A, Uibo R. Review on autoimmune
reactions in female infertility: antibodies to follicle stimulating
hormone. Clin Dev Immunol. 2012;2012:762541.
99. Aittomaki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J,
Gromoll J, et al. Mutation in the follicle-stimulating hormone re-
ceptor gene causes hereditary hypergonadotropic ovarian failure.
Cell. 1995;82:959–68.
100. Layman LC, Lee EJ, Peak DB, Namnoum AB, Vu KV, van
Lingen BL, et al. Delayed puberty and hypogonadism caused by
mutations in the follicle-stimulating hormone beta-subunit gene.
N Engl J Med. 1997;337:607–11.
101. Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV,
Mahale SD. Poor ovarian response to gonadotrophin stimulation is
1279J Assist Reprod Genet (2021) 38:1265–1280
associated with FSH receptor polymorphism. Reprod BioMed
Online. 2009;18:509–15.
102. Huang X, Li L, Hong L, Zhou W, Shi H, Zhang H, et al. The
Ser680Asn polymorphism in the follicle-stimulating hormone re-
ceptor gene is associated with the ovarian response in controlled
ovarian hyperstimulation. Clin Endocrinol. 2015;82:577–83.
103. Galvao A, Segers I, Smitz J, Tournaye H, De Vos M. In vitro
maturation (IVM) of oocytes in patients with resistant ovary syn-
drome and in patients with repeated deficient oocyte maturation. J
Assist Reprod Genet. 2018;35:2161–71.
104. Li Y, Pan P, Yuan P, Qiu Q, Yang D. Successful live birth in a
woman with resistant ovary syndrome following in vitro matura-
tion of oocytes. J Ovarian Res. 2016;9:54.
105. Lensen SF, Wilkinson J, Leijdekkers JA, La Marca A, Mol BWJ,
Marjoribanks J, et al. Individualised gonadotropin dose selection
using markers of ovarian reserve for women undergoing in vitro
fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Cochrane Database Syst Rev. 2018;2:CD012693.
106. Liu J, Lu G, Qian Y, Mao Y, Ding W. Pregnancies and births
achieved from in vitro matured oocytes retrieved from poor re-
sponders undergoing stimulation in in vitro fertilization cycles.
Fertil Steril. 2003;80:447–9.
107. Braga DP, Figueira Rde C, Ferreira RC, Pasqualotto FF, Iaconelli
A Jr, Borges E Jr. Contribution of in-vitro maturation in ovarian
stimulation cycles of poor-responder patients. Reprod BioMed
Online. 2010;20:335–40.
108. Chian RC, Lim JH, Tan SL. State of the art in in-vitro oocyte
maturation. Curr Opin Obstet Gynecol. 2004;16:211–9.
109. Nogueira D, Sadeu JC, Montagut J. In vitro oocyte maturation:
current status. Semin Reprod Med. 2012;30:199–213.
110. Walls ML, Ryan JP, Keelan JA, Hart R. In vitro maturation is
associated with increased early embryo arrest without impairing
morphokinetic development of useable embryos progressing to
blastocysts. Hum Reprod. 2015;30:1842–9.
111. Rudak E, Dor J, Kimchi M, Goldman B, Levran D, Mashiach S.
Anomalies of human oocytes from infertile women undergoing
treatment by in vitro fertilization. Fertil Steril. 1990;54:292–6.
112. Feng R, Sang Q, Kuang Y, Sun X, Yan Z, Zhang S, et al.
Mutations in TUBB8 and human oocyte meiotic arrest. N Engl J
Med. 2016;374:223–32.
113. Hourvitz A,Maman E, BrengauzM,Machtinger R, Dor J. In vitro
maturation for patients with repeated in vitro fertilization failure
due to “oocyte maturation abnormalities”. Fertil Steril. 2010;94:
496–501.
114. Strowitzki T, Bruckner T, Roesner S. Maternal and neonatal out-
come and children’s development after medically assisted repro-
duction with in-vitro matured oocytes-a systematic review and
meta-analysis. Hum Reprod Update. 2021;27:460–73.
115. Buckett WM, Chian RC, Dean NL, Sylvestre C, Holzer HE, Tan
SL. Pregnancy loss in pregnancies conceived after in vitro oocyte
maturat ion, conventional in vi t ro fer t i l izat ion, and
intracytoplasmic sperm injection. Fertil Steril. 2008;90:546–50.
116. Mostinckx L, Segers I, Belva F, Buyl R, Santos-Ribeiro S,
Blockeel C, et al. Obstetric and neonatal outcome of ART in
patients with polycystic ovary syndrome: IVM of oocytes versus
controlled ovarian stimulation. Hum Reprod. 2019;34:1595–607.
117. Kuhtz J, Romero S, De Vos M, Smitz J, Haaf T, Anckaert E.
Human in vitro oocyte maturation is not associated with increased
imprinting error rates at LIT1, SNRPN, PEG3 and GTL2. Hum
Reprod. 2014;29:1995–2005.
118. Pliushch G, Schneider E, Schneider T, El Hajj N, Rosner S,
Strowitzki T, et al. In vitro maturation of oocytes is not associated
with altered deoxyribonucleic acid methylation patterns in chil-
dren from in vitro fertilization or intracytoplasmic sperm injection.
Fertil Steril. 2015;103:720–7.e1.
119. Roesner S, vonWolffM, ElsaesserM, Roesner K, Reuner G, Pietz
J, et al. Two-year development of children conceived by IVM: a
prospective controlled single-blinded study. Hum Reprod.
2017;32:1341–50.
120. Soderstrom-Anttila V, T Salokorpi, M Pihlaja, S Serenius-Sirve
AM Suikkari. Obstetric and perinatal outcome and preliminary
results of development of children born after in vitro maturation
of oocytes. Hum Reprod. 2006.
121. Shu-Chi M, Jiann-Loung H, Yu-Hung L, Tseng-Chen S, Ming I,
Tsu-Fuh Y. Growth and development of children conceived by in-
vitro maturation of human oocytes. Early Hum Dev. 2006;82:
677–82.
122. Yu EJ, Yoon TK, Lee WS, Park EA, Heo JY, Ko YK, et al.
Obstetrical, neonatal, and long-term outcomes of children con-
ceived from in vitro matured oocytes. Fertil Steril. 2019;112:
691–9.
123. Vesztergom D, Segers I, Mostinckx L, Blockeel C, De Vos M.
Live births after in vitro maturation of oocytes in women who had
suffered adnexal torsion and unilateral oophorectomy following
conventional ovarian stimulation. J Assist Reprod Genet. 2021.
124. Paulson RJ, Fauser B, Vuong LTN, Doody K. Can we modify
assisted reproductive technology practice to broaden reproductive
care access? Fertil Steril. 2016;105:1138–43.
125. Braam SC, Ho VNA, Pham TD, Mol BW, van Wely M, Vuong
LN. In-vitro maturation versus IVF: a cost-effectiveness analysis.
Reprod BioMed Online. 2021;42:143–9.
126. Rose BI, Laky D, Miller B. The case for in vitro maturation lower
cost and more patient friendly. J Reprod Med. 2014;59:571–8.
127. Rose BI. Approaches to oocyte retrieval for advanced reproduc-
tive technology cycles planning to utilize in vitro maturation: a
review of the many choices to be made. J Assist Reprod Genet.
2014;31:1409–19.
128. Bertoldo MJ, Smitz J, Wu LE, Lee HC, Woodruff TK, Gilchrist
RB. Trends Endocrinol Metab. 2020;31:708–11.
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
1280 J Assist Reprod Genet (2021) 38:1265–1280
